Compare Dominari Holdings, Inc. with Similar Stocks
Dashboard
1
With a growth in Net Sales of 1157.01%, the company declared Very Positive results in Sep 25
- OPERATING CASH FLOW(Y) Highest at USD -7.24 MM
- NET PROFIT(HY) Higher at USD -21.34 MM
- ROCE(HY) Highest at 88.88%
2
With ROE of -24.90%, it has a attractive valuation with a 0.23 Price to Book Value
3
Majority shareholders : Mutual Funds
Stock DNA
Pharmaceuticals & Biotechnology
USD 48 Million (Micro Cap)
NA (Loss Making)
NA
7.40%
-0.84
-24.90%
0.23
Revenue and Profits:
Net Sales:
31 Million
(Quarterly Results - Dec 2025)
Net Profit:
-132 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-2.41%
0%
-2.41%
6 Months
-23.53%
0%
-23.53%
1 Year
-31.58%
0%
-31.58%
2 Years
55.56%
0%
55.56%
3 Years
23.81%
0%
23.81%
4 Years
-40.52%
0%
-40.52%
5 Years
-76.53%
0%
-76.53%
Dominari Holdings, Inc. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
151.48%
EBIT Growth (5y)
-236.24%
EBIT to Interest (avg)
-15.42
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.44
Sales to Capital Employed (avg)
0.28
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
9.01%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
0.23
EV to EBIT
2.28
EV to EBITDA
2.30
EV to Capital Employed
-3.69
EV to Sales
-1.28
PEG Ratio
NA
Dividend Yield
7.40%
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
-24.90%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Bearish
RSI
Bullish
No Signal
Bollinger Bands
Mildly Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Mildly Bearish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
Mildly Bearish
No Trend
Shareholding Snapshot : Dec 2025
Shareholding Compare (%holding) 
Majority shareholders
Domestic Funds
Domestic Funds
Held in 6 Schemes (2.95%)
Foreign Institutions
Held by 8 Foreign Institutions (0.68%)
Strategic Entities with highest holding
Highest Public shareholder
Quarterly Results Snapshot (Consolidated) - Dec'25 - YoY
Dec'25
Dec'24
Change(%)
Net Sales
30.60
9.30
229.03%
Operating Profit (PBDIT) excl Other Income
-123.60
0.80
-15,550.00%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
-131.70
1.10
-12,072.73%
Operating Profit Margin (Excl OI)
-4,034.30%
74.10%
-410.84%
USD in Million.
Net Sales
YoY Growth in quarter ended Dec 2025 is 229.03% vs 745.45% in Dec 2024
Consolidated Net Profit
YoY Growth in quarter ended Dec 2025 is -12,072.73% vs 115.94% in Dec 2024
Annual Results Snapshot (Consolidated) - Dec'25
Dec'25
Dec'24
Change(%)
Net Sales
122.80
26.70
359.93%
Operating Profit (PBDIT) excl Other Income
-13.30
-15.00
11.33%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
-20.50
-14.70
-39.46%
Operating Profit Margin (Excl OI)
-110.80%
-580.10%
46.93%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2025 is 359.93% vs 2,866.67% in Dec 2024
Consolidated Net Profit
YoY Growth in year ended Dec 2025 is -39.46% vs 35.81% in Dec 2024
About Dominari Holdings, Inc. 
Dominari Holdings, Inc.
Pharmaceuticals & Biotechnology
Aikido Pharma Inc., formerly Spherix Incorporated, is a biotechnology company. The Company is focused on developing a diverse portfolio of small-molecule anti-cancer therapeutics. Its diverse pipeline of therapeutics includes therapies for pancreatic cancer, acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). In addition, the Company is constantly seeking to grow its pipeline to treat its unmet medical needs in oncology.
Company Coordinates 
Company Details
ONE ROCKEFELLER PLAZA, 11TH FLOOR , NEW YORK NY : 10020
Registrar Details






